Trump's threat of imposing a tariff on Denmark over desires to acquire Greenland has caught the attention of one of the ...

U.S. stock futures point lower as investors evaluate disappointing tech earnings, shares of Alphabet drop as the Google parent's cloud revenue falls short of estimates, and Advanced Micro Devices ...

Sales of Novo Nordisk’s obesity drug, Wegovy, rose by more than 50 per cent last year, helping the Danish drugmaker beat revenue expectations.

From Aug. 1 to the end of the year, Medicaid beneficiaries received 33,035 claims for GLP-1 drugs for weight loss, a number ...

There is no sign of a slowdown in Johnston County's rapid growth, meaning things like cost of living and infrastructure are ...

North Carolina achieved a record-breaking year for life sciences investments in 2024. Twenty-five companies announced ...

Obesity drugs - especially Novo Nordic's Ozempic - dominated healthcare headlines in 2024, but Matt Miskin of John Hancock ...

Equities research analysts at Cantor Fitzgerald decreased their FY2024 earnings per share (EPS) estimates for Novo Nordisk ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of GLP-1 drugs for weight loss and diabetes treatment has reported clinical ...